Stivarga Regulatory Post-Marketing Surveillance Study in Korea (StivargaPMS)
To investigate and collect post-marketing data on the safety of Stivarga in real world practice in its registered indication(s) as required by Health Authority.
- Signed and dated informed consent - Patients diagnosed with histologically confirmed metastatic colorectal cancer and/or metastatic or unresectable locally advanced gastrointestinal stromal tumors and/or HCC who have been previously treated with sorafenib by physician - Patients who are prescribed with Stivarga tablet 40mg(Regorafenib) for the first time -
- Patients participating in an investigational program with interventions outside of routine clinical practice - All contra-indications according to the local marketing authorization have to be considered.
Many Locations, South Korea
E-mail: [email protected]
Phone: Not Available
Stivarga® Regulatory Post-Marketing Surveillance Study in Korea